The Claim
Rapamycin (sirolimus) received US Food and Drug Administration approval in 1999 for use as an immunosuppressant medication in organ transplantation, specifically in clinical scenarios where avoidance of calcineurin inhibitors is indicated, such as in transplant recipients with skin cancer or other special circumstances.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A drug called Rapamycin got approved by the US government in 1999 to help prevent organ rejection in transplant patients, especially when doctors want to avoid using another type of anti-rejection medicine.
See the scientific wording
Rapamycin was approved by the US Food and Drug Administration in 1999 as an immunosuppressant for use in transplantation, particularly in situations where calcineurin inhibitor avoidance is desirable such as in skin cancer or other special circumstances.
Score breakdown, mechanism chain, raw evidence, ideal studies needed
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.